The B3GNT9 Knockout HEK293T Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population in which the B3GNT9 gene has been disrupted, providing a robust loss-of-function model for studying glycosylation pathways. This polyclonal population is derived from the widely used HEK293T host cell line and serves as a research tool to interrogate the role of B3GNT9 in poly-N-acetyllactosamine (poly-LacNAc) synthesis and cell surface carbohydrate remodeling. The knockout model enables investigation of how B3GNT9-dependent glycan extensions influence glycoprotein and glycolipid functions in a human cell context.
HEK293T cells are an immortalized human embryonic kidney cell line expressing the SV40 large T antigen, attributes that confer high transfection efficiency, robust protein expression, and reliable viral production capabilities. This cell line is extensively employed in transient transfection studies, viral vector production, and recombinant protein manufacturing. Its epithelial origin and ease of manipulation make it an ideal platform for engineering glycosylation pathways, particularly given the endogenous expression of relevant glycosyltransferases and nucleotide sugar transporters that support complex glycan biosynthesis.
B3GNT9 encodes a glycosyltransferase that catalyzes the transfer of N-acetylglucosamine (GlcNAc) from the donor substrate UDP-GlcNAc to galactose residues in a ??1,3-linkage, a key step in the elongation of poly-LacNAc chains on glycoproteins and glycolipids. This enzyme functions within the O-glycan biosynthesis pathway and is activated by metabolic signals and UDP-GlcNAc levels. B3GNT9 interacts directly with UDP-GlcNAc and collaborates with other glycosyltransferases, such as galactosyltransferases and glycosylhydrolases, to modify diverse downstream targets including integrins, growth factor receptors, and glycolipid substrates. Through these interactions, B3GNT9 influences cell surface carbohydrate architecture and potentially modulates processes such as cell adhesion and receptor-mediated signaling.
Knockout of B3GNT9 in the HEK293T background enables dissection of how the absence of this specific glycosyltransferase alters the cellular glycome. The disrupted poly-LacNAc extension on glycoprotein substrates such as integrins and growth factor receptors can affect their stability, trafficking, or ligand interactions, providing a system to study glycosylation-dependent regulation of cell signaling and adhesion. The high transfectability of HEK293T cells further facilitates rescue experiments or co-expression of mutant glycosyltransferases, allowing precise structure-function analyses. This model is particularly valuable for investigating how changes in cell surface glycosylation contribute to disease states such as cancer, congenital disorders of glycosylation, and immune dysfunction.
Key research applications include glycomic profiling of glycoproteins and glycolipids using mass spectrometry, lectin blotting, and flow cytometry with lectins to map B3GNT9-dependent glycan epitopes. Researchers can employ metabolic labeling with azido-sugars, immunofluorescence for cell surface glycans, and western blotting to assess glycoprotein modifications, while RT-qPCR confirms B3GNT9 transcript loss. This knockout population supports cancer biology studies examining aberrant glycosylation, cell surface engineering efforts, and host-pathogen interaction assays where glycan structures are critical. For detailed protocols, validation data, or bulk quantities, please contact Ascent Research.
